Category Archives: Global News Feed

Melanocortin drug NEURACTHEL® (ACTH) added for neurological, endocrinological and degenerative disorders Melanocortin drug NEURACTHEL® (ACTH) added for neurological, endocrinological and degenerative disorders

Here is the original post:
CLINUVEL Expands Pharmaceutical Portfolio

HONG KONG, Shanghai and FLORHAM PARK, N.J., Nov. 07, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new analyses and updates on the ongoing studies of HMPL-523 and HMPL-306 will be presented at the upcoming 63rd American Society for Hematology’s (ASH) Annual Meeting and Exposition, taking place on December 11-14, 2021. The meeting will be held virtually and in person at the Georgia World Congress Center in Atlanta, Georgia US.

Read more here:
HUTCHMED Highlights HMPL-523 Clinical Data to be Presented at the 2021 ASH Annual Meeting

In accordance with a decision by the majority of shareholders at the AS Olainfarm Extraordinary Meeting of Shareholders held on 14 October 2021, AS Olainfarm shares are being delisted from the regulated market, and the company’s shares will no longer be traded on the NASDAQ Riga Stock Exchange. In order to ensure that AS Olainfarm shareholders have the opportunity to receive fair value for their shares, the mandatory buy-back of AS Olainfarm shares is currently taking place. It is being conducted in accordance with the provisions of the Republic of Latvia’s Financial Instrument Market Law, and is being overseen by the Financial and Capital Market Commission (FCMC).

Read the original post:
AS AB CITY starts the mandatory buy-back of AS Olainfarm shares

– One of the largest private financings of a UK biotech company, and the largest from a single source – continues Blackstone conviction in the country

The rest is here:
Blackstone Life Sciences to invest up to $250 million in Autolus Therapeutics to develop obe-cel in adult Acute Lymphoblastic Leukemia (ALL) and...

QuantuMDx secures £15 million equity investment from Vita Spring and enters into Cooperation Agreement discussions with Sansure Biotech

Read this article:
QuantuMDx secures £15 million equity investment from Vita Spring and enters into Cooperation Agreement discussions with Sansure Biotech

NEW YORK, NY, Oct. 15, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a New York based diversified Life Sciences Company, today announced that it has commenced the development of a proprietary Ashwagandha extract infused supplement chewing gum.  This proposed product will incorporate the Company’s considerable expertise in developing proprietary chewing gums, as well as its unwavering commitment to innovation, while always adhering to the highest moral, safety, and quality standards.

The rest is here:
Tauriga Sciences Inc. Commences Development of Ashwagandha Infused Chewing Gum

WALTHAM, Mass. and STOCKHOLM, Sweden, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending the marketing authorization of Aspaveli® (pegcetacoplan) for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) who are anemic after treatment with a C5 inhibitor for at least three months. The positive opinion from the CHMP is now referred to the European Commission for an approval decision.

Read this article:
Apellis and Sobi Receive Positive CHMP Opinion for Aspaveli® (pegcetacoplan) for the Treatment of PNH

Silence Announces Proposed Cancellation of Admission of its Ordinary Shares to Trading on AIM and Transition of its Primary Trading Venue to the Nasdaq Global Market

Read more:
Silence Announces Proposed Cancellation of Admission of its Ordinary Shares to Trading on AIM and Transition of its Primary Trading Venue to the...

COPENHAGEN, Denmark, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), today announced the U.S. commercial launch of SKYTROFA (lonapegsomatropin-tcgd), its once-weekly treatment for the treatment of pediatric patients one year and older who weigh at least 11.5 kg (25.4 lb) and have growth failure due to inadequate secretion of endogenous growth hormone (GH). SKYTROFA (lonapegsomatropin-tcgd) is available by prescription and distributed through a network of specialty pharmacies across the United States.

Read more from the original source:
Ascendis Pharma A/S Announces U.S. Commercial Launch of SKYTROFA® (Lonapegsomatropin-tcgd), the First and Only FDA Approved Once-Weekly Treatment for...

CAMBRIDGE, Mass., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today announced an oral presentation at the European Society of Gene and Cell Therapy (ESGCT) Annual Virtual Congress taking place October 19-22. The presentation will highlight preclinical advances from the company’s retina therapeutic area.

See the rest here:
Generation Bio to Present at European Society of Gene and Cell Therapy 2021 Annual Virtual Congress